Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits.
Miguel M Carvalho, Filipa L Campos, Bárbara Coimbra, José M Pêgo, Carla Rodrigues, Rui Lima, Ana J Rodrigues, Nuno Sousa, António J Salgado
Index: Molecular Neurodegeneration 8 , 14, (2013)
Full Text: HTML
Abstract
Parkinson's disease (PD) is a chronic neurodegenerative condition that is characterized by motor symptoms as a result of dopaminergic degeneration, particularly in the mesostriatal pathway. However, in recent years, a greater number of clinical studies have focused on the emergence of non-motor symptoms in PD patients, as a consequence of damage on the mesolimbic and mesocortical dopaminergic networks, and on their significant impact on the quality of life of PD patients. Herein, we performed a thorough behavioral analysis including motor, emotional and cognitive dimensions, of the unilateral medial forebrain bundle (MFB) 6-hydroxidopamine (6-OHDA)-lesioned model of PD, and further addressed the impact of pharmacological interventions with levodopa and antidepressants on mood dimensions.Based on apomorphine-induced turning behaviour and degree of dopaminergic degeneration, animals submitted to MFB lesions were subdivided in complete and incomplete lesion groups. Importantly, this division also translated into a different severity of motor and exploratory impairments and depressive-like symptoms; in contrast, no deficits in anxiety-like and cognitive behaviors were found in MFB-lesioned animals. Subsequently, we found that the exploratory and the anhedonic behavioural alterations of MFB-lesioned rats can be partially improved with the administration of both levodopa or the antidepressant bupropion, but not paroxetine.Our results suggest that this model is a relevant tool to study the pathophysiology of motor and non-motor symptoms of PD. In addition, the present data shows that pharmacological interventions modulating dopaminergic transmission are also relevant to revert the non-motor behavioral deficits found in the disease.
Related Compounds
Related Articles:
2013-02-01
[J. Clin. Psychopharmacol. 33(1) , 3-10, (2013)]
Chronic angle-closure glaucoma related to paroxetine treatment.
2013-07-01
[Semin. Ophthalmol. 28(4) , 244-6, (2013)]
Paroxetine (Brisdelle) for hot flashes.
2013-10-28
[Med. Lett. Drugs Ther. 55(1428) , 85-6, (2013)]
FDA Approval of Paroxetine for Menopausal Hot Flushes
2014-05-08
[N. Engl. J. Med. 370(19) , 1777-9, (2014)]
Serotonin and yawning: a potential adverse drug reaction during antidepressant therapy
2013-10-16
[Presse Med. 43(10 Pt 1) , 1135-6, (2014)]